Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager indicated for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Note: This medicine has received conditional approval based on response rates. Ongoing studies aim to confirm its clinical benefits.

Recommended Dosage: Patients must be premedicated prior to each dose in Cycles 1 and 2 to lower the risk of cytokine release syndrome (CRS) and infusion-related reactions. Lunsumio is to be administered exclusively via intravenous (IV) infusion. Each treatment cycle spans 21 days.

Dosage Schedule:

• Cycle 1:
  • Day 1: 1 mg IV infusion over at least 4 hours
  • Day 8: 2 mg IV infusion over at least 4 hours
  • Day 15: 60 mg IV infusion over at least 4 hours

     

• Cycle 2:
  • Day 1: 60 mg IV over 2 hours (if Cycle 1 was well-tolerated)

     

• Cycle 3+:
  • Day 1: 30 mg IV over 2 hours (if earlier cycles were well-tolerated)

     

Treatment continues for up to 8 cycles unless disease progression or unacceptable toxicity occurs. If complete response is achieved, no treatment beyond 8 cycles is required. In cases of partial response or stable disease, therapy may continue for up to 17 cycles.